Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
Bladder, Urologic
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
Enfortumab Vedotin (ASG-22CE), MK-3475, Nivolumab (BMS-936558), Pembrolizumab (MK-3475), Sitravatinib
Davis, Nancy
International
Vanderbilt University
07-24-2019
Treatment
VICCURO18175
NCT03606174

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Diagnosis of urothelial carcinoma

Adequate bone marrow and organ function



Exclusion Criteria:

Uncontrolled tumor in the brain

Unacceptable toxicity with prior checkpoint inhibitor

Impaired heart function

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: